Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Choksi AsiaBOM:530427 +1.56%52 EBITDA Margin % is 19.50% as of Mar. 2026, which is 261% above its 10-year median of 5.40. GuruFocus rates BOM:530427 with a GF Score™ of 52/100. The stock has 8 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Choksi Asia ranks better than 69.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Choksi Asia's EBITDA for the
three
months ended in Mar. 2026 was ₹23.1 Mil. Choksi Asia's Revenue for the
three
months ended in Mar. 2026 was ₹118.6 Mil. Therefore, Choksi Asia's EBITDA margin for the quarter that ended in Mar. 2026 was 19.50%.
Choksi Asia (BOM:530427) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Choksi Asia EBITDA Margin % Related Terms
Choksi Asia EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Choksi Asia's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530427 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Choksi Asia's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Choksi Asia EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Choksi Asia's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Choksi Asia's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Choksi Asia (BOM:530427) has a EBITDA Margin % of 19.50% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Choksi Asia and its competitors. This is 261% above median its historical median of 5.40. According to the industry distribution chart, Choksi Asia ranks #249 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 30.6%.
Is Choksi Asia's EBITDA Margin % too high?
Choksi Asia's current EBITDA Margin % of 19.50% is 261% above median its 10-year median of 5.40. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Choksi Asia's value of 19.50% is 159.3% above this industry median. Based on the distribution chart, Choksi Asia ranks #249 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Choksi Asia has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Choksi Asia's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Choksi Asia ranks #249 out of 815 companies for EBITDA Margin %. This puts Choksi Asia in the upper half of its industry. The industry median EBITDA Margin % is 7.52. Choksi Asia's value of 19.50% is 159.3% above this benchmark. While the company's 10-year median is 5.40 vs. the industry median of 7.52, Choksi Asia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Choksi Asia's current EBITDA Margin % of 19.50% is 159.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Choksi Asia and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Choksi Asia's current EBITDA Margin % is 19.50%, which is 261% above median its own 10-year median of 5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Choksi Asia stock overvalued right now?
Choksi Asia (BOM:530427) has a current EBITDA Margin % of 19.50%. The current EBITDA Margin % is 19.50%, which is 261% above median its 10-year median of 5.40 and 159.3% above the Medical Devices & Instruments industry median of 7.52. Choksi Asia's overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Choksi Asia (BOM:530427), the current EBITDA Margin % is 19.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Choksi Asia Ltd formerly Choksi Imaging Ltd is an India-based company engaged in the manufacturing of photosensitized materials, medical X-rays, and other healthcare products. The company sells and derives revenue from products like X-ray films, ultrasound, computed radiography systems, specialty X-ray films, etc. In addition, the company also offers maintenance services for X-ray processors, equipment, and computer radiography systems. The firm provides various photographic, and ultrasonic sound services in association with Protec, Medtron, and others.
52GF Score
Get the complete analysis for BOM:530427
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530427 has been successfully added to your 
